Results 81 to 90 of about 13,106 (183)
American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1879-1883, August 2026.ABSTRACT Noonan syndrome (NS) is a genetically heterogeneous disorder characterized by a broad spectrum of clinical features resulting from dysregulation of the RAS/MAPK pathway. Although complex genotypes are increasingly recognized in NS, cases harboring two distinct pathogenic variants in different NS genes remain extremely rare.
Francesco Prevedello +10 more
wiley +1 more source
Marked Bone Marrow Eosinophilia Post‐Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia
International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski +2 more
wiley +1 more source
Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review
Cancer Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi +17 more
wiley +1 more source
Genes, Chromosomes and Cancer, Volume 65, Issue 8, August 2026.ABSTRACT Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease‐associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb ...
Madilyn R. Stahl +4 more
wiley +1 more source
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
Cancer Management and Research, 2009 KS Götze, C Müller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universität München, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders ...
KS Götze +2 more
doaj
HemaSphere, Volume 10, Issue 8, August 2026.Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li +36 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a high risk of relapse. Leukemia cutis is characterized by the presence of neoplastic leukocytes infiltrating the skin. Here, we present a previously treated AML patient who relapsed with isolated leukemia cutis without bone marrow involvement. Fluorescence in
Bana Antonios +9 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Introduction Prognostic scoring systems in MDS lack functional status measures. We sought to evaluate the influence of frailty on overall survival and care utilization in a national cohort. We conducted a retrospective study in the US Veterans Affairs Healthcare System of patients with MDS initiated on hypomethylating agents (HMAs) from 2004 ...
Anahid Hamparsumian +9 more
wiley +1 more source
Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
MedComm, Volume 7, Issue 8, August 2026.Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge +5 more
wiley +1 more source